Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 plus tislelizumab versus platinum-etoposide plus tislelizumab in first-line extensive-stage small cell lung cancer
CTR20261154Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Jun 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan, tislelizumab, carboplatin, etoposide in small cell lung cancer (SCLC), sponsored by Biokin Pharmaceutical. Started Jun 2026; status: active.
02
Drugs
izalontamab brengitecantislelizumabcarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20261154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261154.